Annual Total Liabilities
$7.11 B
+$556.60 M+8.50%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual total liabilities is currently $7.11 billion, with the most recent change of +$556.60 million (+8.50%) on 31 December 2023. During the last 3 years, it has risen by +$969.10 million (+15.79%). REGN annual total liabilities is now at all-time high.REGN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$8.12 B
+$235.00 M+2.98%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly total liabilities is currently $8.12 billion, with the most recent change of +$235.00 million (+2.98%) on 30 September 2024. Over the past year, it has increased by +$857.10 million (+11.81%). REGN quarterly total liabilities is now at all-time high.REGN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.5% | +11.8% |
| 3 y3 years | +15.8% | +26.6% |
| 5 y5 years | +138.7% | +136.3% |
REGN Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +15.8% | at high | +30.1% |
| 5 y | 5 years | at high | +138.7% | at high | +136.3% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Regeneron Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $8.12 B(+3.0%) |
| June 2024 | - | $7.88 B(+6.8%) |
| Mar 2024 | - | $7.38 B(+3.8%) |
| Dec 2023 | $7.11 B(+8.5%) | $7.11 B(-2.1%) |
| Sept 2023 | - | $7.26 B(+9.3%) |
| June 2023 | - | $6.64 B(+1.1%) |
| Mar 2023 | - | $6.56 B(+0.2%) |
| Dec 2022 | $6.55 B(-1.7%) | $6.55 B(+5.0%) |
| Sept 2022 | - | $6.24 B(-4.3%) |
| June 2022 | - | $6.52 B(+1.3%) |
| Mar 2022 | - | $6.43 B(-3.5%) |
| Dec 2021 | $6.67 B(+8.6%) | $6.67 B(+3.9%) |
| Sept 2021 | - | $6.41 B(+0.9%) |
| June 2021 | - | $6.36 B(+9.7%) |
| Mar 2021 | - | $5.80 B(-5.6%) |
| Dec 2020 | $6.14 B(+65.2%) | $6.14 B(+3.0%) |
| Sept 2020 | - | $5.96 B(+10.9%) |
| June 2020 | - | $5.37 B(+48.2%) |
| Mar 2020 | - | $3.62 B(-2.4%) |
| Dec 2019 | $3.72 B(+24.8%) | $3.72 B(+8.2%) |
| Sept 2019 | - | $3.43 B(+0.5%) |
| June 2019 | - | $3.42 B(+0.2%) |
| Mar 2019 | - | $3.41 B(+14.5%) |
| Dec 2018 | $2.98 B(+13.6%) | $2.98 B(+1.4%) |
| Sept 2018 | - | $2.94 B(+6.2%) |
| June 2018 | - | $2.77 B(-1.4%) |
| Mar 2018 | - | $2.81 B(+7.1%) |
| Dec 2017 | $2.62 B(+3.8%) | $2.62 B(-1.1%) |
| Sept 2017 | - | $2.65 B(+2.5%) |
| June 2017 | - | $2.59 B(-12.4%) |
| Mar 2017 | - | $2.95 B(+16.9%) |
| Dec 2016 | $2.52 B(+29.2%) | $2.52 B(+8.0%) |
| Sept 2016 | - | $2.34 B(+9.8%) |
| June 2016 | - | $2.13 B(-0.5%) |
| Mar 2016 | - | $2.14 B(+9.5%) |
| Dec 2015 | $1.95 B(+51.8%) | $1.95 B(+3.6%) |
| Sept 2015 | - | $1.89 B(+58.7%) |
| June 2015 | - | $1.19 B(-3.1%) |
| Mar 2015 | - | $1.23 B(-4.7%) |
| Dec 2014 | $1.29 B(+28.9%) | $1.29 B(+8.4%) |
| Sept 2014 | - | $1.19 B(+9.2%) |
| June 2014 | - | $1.09 B(+3.6%) |
| Mar 2014 | - | $1.05 B(+5.0%) |
| Dec 2013 | $998.94 M(+19.6%) | $998.94 M(+5.1%) |
| Sept 2013 | - | $950.24 M(+7.4%) |
| June 2013 | - | $884.92 M(+1.8%) |
| Mar 2013 | - | $869.65 M(+4.1%) |
| Dec 2012 | $835.11 M(-0.3%) | $835.11 M(-2.3%) |
| Sept 2012 | - | $854.59 M(-1.0%) |
| June 2012 | - | $862.84 M(+2.0%) |
| Mar 2012 | - | $846.13 M(+1.0%) |
| Dec 2011 | $837.85 M(+49.2%) | $837.85 M(+51.0%) |
| Sept 2011 | - | $554.78 M(-2.5%) |
| June 2011 | - | $568.83 M(+2.3%) |
| Mar 2011 | - | $556.20 M(-1.0%) |
| Dec 2010 | $561.62 M(+63.1%) | $561.62 M(-5.5%) |
| Sept 2010 | - | $594.37 M(+41.7%) |
| June 2010 | - | $419.43 M(+4.6%) |
| Mar 2010 | - | $400.88 M(+16.4%) |
| Dec 2009 | $344.44 M(+13.8%) | $344.44 M(+7.7%) |
| Sept 2009 | - | $319.75 M(-3.6%) |
| June 2009 | - | $331.84 M(+22.4%) |
| Mar 2009 | - | $271.10 M(-10.4%) |
| Dec 2008 | $302.71 M(-36.4%) | $302.71 M(-22.2%) |
| Sept 2008 | - | $388.96 M(-2.8%) |
| June 2008 | - | $400.23 M(-14.9%) |
| Mar 2008 | - | $470.27 M(-1.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $475.99 M(+29.2%) | $475.99 M(+12.9%) |
| Sept 2007 | - | $421.70 M(+0.8%) |
| June 2007 | - | $418.52 M(+3.4%) |
| Mar 2007 | - | $404.74 M(+9.8%) |
| Dec 2006 | $368.47 M(+19.1%) | $368.47 M(+25.9%) |
| Sept 2006 | - | $292.71 M(-0.6%) |
| June 2006 | - | $294.56 M(-1.7%) |
| Mar 2006 | - | $299.77 M(-3.1%) |
| Dec 2005 | $309.50 M(+6.5%) | $309.50 M(+9.4%) |
| Sept 2005 | - | $282.89 M(+0.4%) |
| June 2005 | - | $281.89 M(-0.9%) |
| Mar 2005 | - | $284.51 M(-2.1%) |
| Dec 2004 | $290.56 M(-15.0%) | $290.56 M(-1.1%) |
| Sept 2004 | - | $293.81 M(-1.4%) |
| June 2004 | - | $298.04 M(-1.3%) |
| Mar 2004 | - | $302.07 M(-11.7%) |
| Dec 2003 | $341.91 M(+39.2%) | $341.91 M(-0.7%) |
| Sept 2003 | - | $344.30 M(+33.6%) |
| June 2003 | - | $257.70 M(-2.7%) |
| Mar 2003 | - | $264.83 M(+7.8%) |
| Dec 2002 | $245.59 M(+7.2%) | $245.59 M(+3.3%) |
| Sept 2002 | - | $237.80 M(+4.6%) |
| June 2002 | - | $227.29 M(-0.9%) |
| Mar 2002 | - | $229.38 M(+0.1%) |
| Dec 2001 | $229.04 M(+776.1%) | $229.04 M(+864.7%) |
| Sept 2001 | - | $23.74 M(+3.2%) |
| June 2001 | - | $23.00 M(-7.2%) |
| Mar 2001 | - | $24.77 M(-5.2%) |
| Dec 2000 | $26.14 M(-4.9%) | $26.14 M(+3.1%) |
| Sept 2000 | - | $25.35 M(-3.1%) |
| June 2000 | - | $26.15 M(-1.1%) |
| Mar 2000 | - | $26.44 M(-3.9%) |
| Dec 1999 | $27.50 M(+7.0%) | $27.50 M(+15.1%) |
| Sept 1999 | - | $23.90 M(-2.0%) |
| June 1999 | - | $24.40 M(-5.8%) |
| Mar 1999 | - | $25.90 M(+0.8%) |
| Dec 1998 | $25.70 M(-12.9%) | $25.70 M(+0.8%) |
| Sept 1998 | - | $25.50 M(-6.6%) |
| June 1998 | - | $27.30 M(+5.0%) |
| Mar 1998 | - | $26.00 M(-11.9%) |
| Dec 1997 | $29.50 M(-3.9%) | $29.50 M(+11.3%) |
| Sept 1997 | - | $26.50 M(-12.0%) |
| June 1997 | - | $30.10 M(+7.1%) |
| Mar 1997 | - | $28.10 M(-8.5%) |
| Dec 1996 | $30.70 M(+18.5%) | $30.70 M(+16.3%) |
| Sept 1996 | - | $26.40 M(-0.4%) |
| June 1996 | - | $26.50 M(+10.0%) |
| Mar 1996 | - | $24.10 M(-6.9%) |
| Dec 1995 | $25.90 M(-4.4%) | $25.90 M(+22.2%) |
| Sept 1995 | - | $21.20 M(-11.7%) |
| June 1995 | - | $24.00 M(+7.6%) |
| Mar 1995 | - | $22.30 M(-17.7%) |
| Dec 1994 | $27.10 M(+41.1%) | $27.10 M(+10.2%) |
| Sept 1994 | - | $24.60 M(-15.5%) |
| June 1994 | - | $29.10 M(+50.8%) |
| Mar 1994 | - | $19.30 M(+0.5%) |
| Dec 1993 | $19.20 M(+79.4%) | $19.20 M(+21.5%) |
| Sept 1993 | - | $15.80 M(+12.9%) |
| June 1993 | - | $14.00 M(+9.4%) |
| Mar 1993 | - | $12.80 M(+19.6%) |
| Dec 1992 | $10.70 M(+37.2%) | $10.70 M(-1.8%) |
| Sept 1992 | - | $10.90 M(+16.0%) |
| June 1992 | - | $9.40 M(+2.2%) |
| Mar 1992 | - | $9.20 M(+17.9%) |
| Dec 1991 | $7.80 M(-40.9%) | $7.80 M(+39.3%) |
| Sept 1991 | - | $5.60 M(-5.1%) |
| June 1991 | - | $5.90 M(-55.3%) |
| Dec 1990 | $13.20 M | $13.20 M |
FAQ
- What is Regeneron Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual total liabilities year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly total liabilities year-on-year change?
What is Regeneron Pharmaceuticals annual total liabilities?
The current annual total liabilities of REGN is $7.11 B
What is the all time high annual total liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total liabilities is $7.11 B
What is Regeneron Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, REGN annual total liabilities has changed by +$556.60 M (+8.50%)
What is Regeneron Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of REGN is $8.12 B
What is the all time high quarterly total liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total liabilities is $8.12 B
What is Regeneron Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, REGN quarterly total liabilities has changed by +$857.10 M (+11.81%)